High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats

Neuroscience Letters

Volumn 551, Issue , 2013, Pages 28-33

  Brückner, Melanie ^a   Lasarzik, Irina ^a   Jahn Eimermacher, Antje ^a   Peetz, Dirk ^a,b   Werner, Christian ^a   Engelhard, Kristin ^a   Thal, Serge C ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

Activated protein C; Coagulation; Drotrecogin alfa; Global cerebral ischemia; Inflammation; Neuroprotection

Indexed keywords

CASPASE 3; DROTRECOGIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; CELL LOSS; CELL SURVIVAL; CLIP; COGNITIVE DEFECT; COMMON CAROTID ARTERY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG HALF LIFE; ENCEPHALITIS; ENZYME ACTIVITY; HEMORRHAGIC HYPOTENSION; MICROGLIA; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION;

ACTIVATED PROTEIN C; APC; BCAO; BILATERAL OCCLUSION OF THE COMMON CAROTID ARTERIES; COAGULATION; DROTRECOGIN ALFA; GLOBAL CEREBRAL ISCHEMIA; INFLAMMATION; MAP; MEAN ARTERIAL BLOOD PRESSURE; NEUROPROTECTION; RECOMBINANT HUMAN APC; RHAPC;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL DEATH; HUMANS; INFUSIONS, INTRAVENOUS; PROTEIN C; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 84882264544     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.06.055     Document Type: Article

References (34)

1. Cheng T., Liu D., Griffin J.H., Fernandez J.A., Castellino F., Rosen E.D., Fukudome K., Zlokovic B.V. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 2003, 9:338-342.
2. Cheng T., Petraglia A.L., Li Z., Thiyagarajan M., Zhong Z., Wu Z., Liu D., Maggirwar S.B., Deane R., Fernandez J.A., LaRue B., Griffin J.H., Chopp M., Zlokovic B.V. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat. Med. 2006, 12:1278-1285.
3. Dahlback B., Villoutreix B.O. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1311-1320.
4. Elphick G.F., Sarangi P.P., Hyun Y.M., Hollenbaugh J.A., Ayala A., Biffl W.L., Chung H.L., Rezaie A.R., McGrath J.L., Topham D.J., Reichner J.S., Kim M. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009, 113:4078-4085.
5. Fernandez J.A., Xu X., Liu D., Zlokovic B.V., Griffin J.H. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells. Mol. Dis. 2003, 30:271-276.
6. Ginsberg M.D. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009, 40:S111-S114.
7. Guo H., Liu D., Gelbard H., Cheng T., Insalaco R., Fernandez J.A., Griffin J.H., Zlokovic B.V. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004, 41:563-572.
8. Hatakeyama T., Matsumoto M., Brengman J.M., Yanagihara T. Immunohistochemical investigation of ischemic and postischemic damage after bilateral carotid occlusion in gerbils. Stroke 1988, 19:1526-1534.
9. Hirose K., Okajima K., Taoka Y., Uchiba M., Tagami H., Nakano K., Utoh J., Okabe H., Kitamura N. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann. Surg. 2000, 232:272-280.
10. Isobe H., Okajima K., Uchiba M., Mizutani A., Harada N., Nagasaki A., Okabe K. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001, 104:1171-1175.
11. Ito D., Tanaka K., Suzuki S., Dembo T., Fukuuchi Y. Enhanced expression of Iba1 ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 2001, 32:1208-1215.
12. Jackson C.V., Bailey B.D., Shetler T.J. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis. J. Pharmacol. Exp. Ther. 2000, 295:967-971.
13. Joyce D.E., Gelbert L., Ciaccia A., DeHoff B., Grinnell B.W. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 2001, 276:11199-11203.
14. Kanji S., Perreault M.M., Chant C., Williamson D., Burry L. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med. 2007, 33:517-523.
15. Kirino T., Tamura A., Sano K. A reversible type of neuronal injury following ischemia in the gerbil hippocampus. Stroke 1986, 17:455-459.
16. Lasarzik I., Cordier J., Peetz D., von Landenberg P., Werner C., Engelhard K., Thal S.C. Effect of autologous blood transfusion on cerebral cytokine expression. J. Neurosurg. Anesthesiol. 2011, 23:215-221.
17. Lin X.J., Li Y.L., Mei G.P., Zou F., He D.D., Liu X.Q., Li Y.J., Zhao T.B., Lin M.T. Activated protein C can be used as a prophylactic as well as a therapeutic agent for heat stroke in rodents. Shock 2009, 32:524-529.
18. Mosnier L.O., Zlokovic B.V., Griffin J.H. The cytoprotective protein C pathway. Blood 2007, 109:3161-3172.
19. Okajima K. Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications. Curr. Vasc. Pharmacol. 2004, 2:125-133.
20. Petraglia A.L., Marky A.H., Walker C., Thiyagarajan M., Zlokovic B.V. Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact. Neurosurgery 2010, 66:165-171. (discussion 171-162).
21. Rogove A.D., Lu W., Tsirka S.E. Microglial activation and recruitment but not proliferation, suffice to mediate neurodegeneration. Cell Death Differ. 2002, 9:801-806.
22. Sato M., Hashimoto H., Kosaka F. Histological changes of neuronal damage in vegetative dogs induced by 18 minutes of complete global brain ischemia: two-phase damage of Purkinje cells and hippocampal CA1 pyramidal cells. Acta Neuropathol. (Berl) 1990, 80:527-534.
23. Shibata M., Kumar S.R., Amar A., Fernandez J.A., Hofman F., Griffin J.H., Zlokovic B.V. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001, 103:1799-1805.
24. Sugawara T., Lewen A., Noshita N., Gasche Y., Chan P.H. Effects of global ischemia duration on neuronal, astroglial, oligodendroglial, and microglial reactions in the vulnerable hippocampal CA1 subregion in rats. J. Neurotrauma 2002, 19:85-98.
25. Teschendorf P., Albertsmeier M., Vogel P., Padosch S.A., Spohr F., Kirschfink M., Schwaninger M., Bottiger B.W., Popp E. Neurological outcome and inflammation after cardiac arrest - effects of protein C in rats. Resuscitation 2008, 79:316-324.
26. Teschendorf P., Padosch S.A., Del Valle Y.F.D., Peter C., Fuchs A., Popp E., Spohr F., Bottiger B.W., Walther A. Effects of activated protein C on post cardiac arrest microcirculation: an in vivo microscopy study. Resuscitation 2009, 80:940-945.
27. Thiyagarajan M., Fernandez J.A., Lane S.M., Griffin J.H., Zlokovic B.V. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J. Neurosci. 2008, 28:12788-12797.
28. Walker C.T., Marky A.H., Petraglia A.L., Ali T., Chow N., Zlokovic B.V. Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res. 2010, 1347:125-131.
29. Wang Y., Thiyagarajan M., Chow N., Singh I., Guo H., Davis T.P., Zlokovic B.V. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 2009, 40:1864-1869.
30. Wang Y., Zhang Z., Chow N., Davis T.P., Griffin J.H., Chopp M., Zlokovic B.V. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 2012, 43:2444-2449.
31. Yamanel L., Mas M.R., Comert B., Isik A.T., Aydin S., Mas N., Deveci S., Ozyurt M., Tasci I., Unal T. The effect of activated protein C on experimental acute necrotizing pancreatitis. Crit. Care 2005, 9:R184-R190.
32. Yamauchi T., Sakurai M., Abe K., Takano H., Sawa Y. Neuroprotective effects of activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 receptor, and its downstream signal phosphorylated serine-threonine kinase after spinal cord ischemia in rabbits. Stroke 2006, 37:1081-1086.
33. Yesilirmak D.C., Kumral A., Tugyan K., Cilaker S., Baskin H., Yilmaz O., Duman N., Ozkan H. Effects of activated protein C on neonatal hypoxic ischemic brain injury. Brain Res. 2008, 1210:56-62.
34. Zhong Z., Ilieva H., Hallagan L., Bell R., Singh I., Paquette N., Thiyagarajan M., Deane R., Fernandez J.A., Lane S., Zlokovic A.B., Liu T., Griffin J.H., Chow N., Castellino F.J., Stojanovic K., Cleveland D.W., Zlokovic B.V. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J. Clin. Invest. 2009, 119:3437-3449.